Global Onychomycosis

Onychomycosis Comprehensive Study by Type (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candida Onychomycosis), Application (Children, Male Adults, Female Adults, Senior Citizens), Treatment (Drug Treatment, Tropical therapy, Debridement), End User (Hospital Pharmacies, Private Pharmacies, Others) Players and Region - Global Market Outlook to 2024

Onychomycosis Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Onychomycosis Market Overview:
Onychomycosis are the fungal infection which occur in fingernails and toenails. Its occur due to moist and humid environments condition. Due to rise in percentage of risk in diabetes, aged people and low immunity increased more susceptible to fungal infection. There has been significant rise in number of people affecting with onychomycosis figure stood up to 11 million in Japan alone in 2018, the future for treatment of onychomychosis looks promising. The major companies are adding more proven technologies systematically and strategically in Asia-Pacific countries as these countries are focused on fastest-growing verticals for treatment of onycomycosis.

Market Drivers
  • Rise in diabetic patients and geriatric patients boost the Onychomycosis Market.
  • Upsurge research and development fuelled up the Onychomycosis Market.

Market Trend
  • Upsurge treatment of Onychomycosis at emerging countries.

Restraints
  • Lack of awareness among the customer hampers the Onychomycosis Market.
  • Side effects of anti fungal drugs imbalance the growth of market.

Opportunities
  • Proliferation of Healthcare infrastructure Leads to Grow the Market.
  • Upsurge Development of Innovative Novel Technology Boost the Onychomycosis Market.

Challenges
  • Limitation due to supply of plastic surgeons are Anticipated to Challenge the Market.


Competitive Landscape:

Some of the key players profiled in the report are Abbott Laboratories Ltd. (United States), GlaxoSmithKline Plc. (United Kingdom), Pfizer Inc. (United States), Valeant Pharmaceuticals (Canada), Galderma (Switzerland), Janssen Biotech (United States), Sciton Inc (United States), Bristol Meyer Squibb Company (United States), Cutera Inc. (United States), Novartis AG (Switzerland), Sanofi Ltd. (France), Topica Pharmaceuticals Inc. (United States), Taro Pharmaceutical Industries Ltd. (United States) and Seren Pharmaceuticals Pvt. Ltd (China). Additionally, following companies can also be profiled that are part of our coverage like Nuvo Research Inc. (Canada), Merz Pharma gmbh & co. kgaa (Germany), NanoBio Corporation (United States), NovaBiotics Ltd (UKUnited Kingdom), Viamet Pharmaceuticals Inc. (United States) and Polichem SA (Switzerland). Analyst at AdvanceMarketAnalytics see United States and United Kingdom Players to retain maximum share of Global Onychomycosis market by 2024. Considering Market by Treatment, the sub-segment i.e. Drug Treatment will boost the Onychomycosis market. Considering Market by End User, the sub-segment i.e. Hospital Pharmacies will boost the Onychomycosis market.

Market Highlights:

In July 2018, Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd. launched an oral antifungal agent NAILIN Capsules 100mg in Japan region. Its offers solution for various symptoms such as pain from misshapen nails, difficulty in putting on shoes and pain upon walking.

“According to U.S. Food and Drug Administration (FDA), its approved the Valeant Pharmaceuticals International, Inc. of Jublia for the Treatment of Onychomycosis. It also approved over-the-counter or prescription topical treatments provide limited efficacy and are often administered in conjunction with frequent debridement, or the scraping, cutting or removal of the nail. Prescription oral treatments are limited by drug interactions and serious safety concerns."

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Onychomycosis market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Onychomycosis market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Onychomycosis Manufacturers, Onychomycosis Traders, End-Use Market Participants of Different Segments of Onychomycosis, Government and Research Organizations, R&D Institutions and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Candida Onychomycosis
By Application
  • Children
  • Male Adults
  • Female Adults
  • Senior Citizens
By Treatment
  • Drug Treatment
  • Tropical therapy
  • Debridement

By End User
  • Hospital Pharmacies
  • Private Pharmacies
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in diabetic patients and geriatric patients boost the Onychomycosis Market.
      • 3.2.2. Upsurge research and development fuelled up the Onychomycosis Market.
    • 3.3. Market Challenges
      • 3.3.1. Limitation due to supply of plastic surgeons are Anticipated to Challenge the Market.
    • 3.4. Market Trends
      • 3.4.1. Upsurge treatment of Onychomycosis at emerging countries.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Onychomycosis, by Type, Application, Treatment, End User and Region (value) (2013-2018)
    • 5.1. Introduction
    • 5.2. Global Onychomycosis (Value)
      • 5.2.1. Global Onychomycosis by: Type (Value)
        • 5.2.1.1. Distal Subungual Onychomycosis
        • 5.2.1.2. White Superficial Onychomycosis
        • 5.2.1.3. Proximal Subungual Onychomycosis
        • 5.2.1.4. Candida Onychomycosis
      • 5.2.2. Global Onychomycosis by: Application (Value)
        • 5.2.2.1. Children
        • 5.2.2.2. Male Adults
        • 5.2.2.3. Female Adults
        • 5.2.2.4. Senior Citizens
      • 5.2.3. Global Onychomycosis by: Treatment (Value)
        • 5.2.3.1. Drug Treatment
        • 5.2.3.2. Tropical therapy
        • 5.2.3.3. Debridement
      • 5.2.4. Global Onychomycosis by: End User (Value)
        • 5.2.4.1. Hospital Pharmacies
        • 5.2.4.2. Private Pharmacies
        • 5.2.4.3. Others
      • 5.2.5. Global Onychomycosis Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Onychomycosis: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2018)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories Ltd. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Valeant Pharmaceuticals (Canada)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Galderma (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Janssen Biotech (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sciton Inc (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bristol Meyer Squibb Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Cutera Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis AG (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Sanofi Ltd. (France)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Topica Pharmaceuticals Inc. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Taro Pharmaceutical Industries Ltd. (United States)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Seren Pharmaceuticals Pvt. Ltd (China)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
  • 7. Global Onychomycosis Sale, by Type, Application, Treatment, End User and Region (value) (2019-2024)
    • 7.1. Introduction
    • 7.2. Global Onychomycosis (Value)
      • 7.2.1. Global Onychomycosis by: Type (Value)
        • 7.2.1.1. Distal Subungual Onychomycosis
        • 7.2.1.2. White Superficial Onychomycosis
        • 7.2.1.3. Proximal Subungual Onychomycosis
        • 7.2.1.4. Candida Onychomycosis
      • 7.2.2. Global Onychomycosis by: Application (Value)
        • 7.2.2.1. Children
        • 7.2.2.2. Male Adults
        • 7.2.2.3. Female Adults
        • 7.2.2.4. Senior Citizens
      • 7.2.3. Global Onychomycosis by: Treatment (Value)
        • 7.2.3.1. Drug Treatment
        • 7.2.3.2. Tropical therapy
        • 7.2.3.3. Debridement
      • 7.2.4. Global Onychomycosis by: End User (Value)
        • 7.2.4.1. Hospital Pharmacies
        • 7.2.4.2. Private Pharmacies
        • 7.2.4.3. Others
      • 7.2.5. Global Onychomycosis Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Onychomycosis: by Type(USD Million)
  • Table 2. Onychomycosis Distal Subungual Onychomycosis , by Region USD Million (2013-2018)
  • Table 3. Onychomycosis White Superficial Onychomycosis , by Region USD Million (2013-2018)
  • Table 4. Onychomycosis Proximal Subungual Onychomycosis , by Region USD Million (2013-2018)
  • Table 5. Onychomycosis Candida Onychomycosis , by Region USD Million (2013-2018)
  • Table 6. Onychomycosis: by Application(USD Million)
  • Table 7. Onychomycosis Children , by Region USD Million (2013-2018)
  • Table 8. Onychomycosis Male Adults , by Region USD Million (2013-2018)
  • Table 9. Onychomycosis Female Adults , by Region USD Million (2013-2018)
  • Table 10. Onychomycosis Senior Citizens , by Region USD Million (2013-2018)
  • Table 11. Onychomycosis: by Treatment(USD Million)
  • Table 12. Onychomycosis Drug Treatment , by Region USD Million (2013-2018)
  • Table 13. Onychomycosis Tropical therapy , by Region USD Million (2013-2018)
  • Table 14. Onychomycosis Debridement , by Region USD Million (2013-2018)
  • Table 15. Onychomycosis: by End User(USD Million)
  • Table 16. Onychomycosis Hospital Pharmacies , by Region USD Million (2013-2018)
  • Table 17. Onychomycosis Private Pharmacies , by Region USD Million (2013-2018)
  • Table 18. Onychomycosis Others , by Region USD Million (2013-2018)
  • Table 19. South America Onychomycosis, by Country USD Million (2013-2018)
  • Table 20. South America Onychomycosis, by Type USD Million (2013-2018)
  • Table 21. South America Onychomycosis, by Application USD Million (2013-2018)
  • Table 22. South America Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 23. South America Onychomycosis, by End User USD Million (2013-2018)
  • Table 24. Brazil Onychomycosis, by Type USD Million (2013-2018)
  • Table 25. Brazil Onychomycosis, by Application USD Million (2013-2018)
  • Table 26. Brazil Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 27. Brazil Onychomycosis, by End User USD Million (2013-2018)
  • Table 28. Argentina Onychomycosis, by Type USD Million (2013-2018)
  • Table 29. Argentina Onychomycosis, by Application USD Million (2013-2018)
  • Table 30. Argentina Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 31. Argentina Onychomycosis, by End User USD Million (2013-2018)
  • Table 32. Rest of South America Onychomycosis, by Type USD Million (2013-2018)
  • Table 33. Rest of South America Onychomycosis, by Application USD Million (2013-2018)
  • Table 34. Rest of South America Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 35. Rest of South America Onychomycosis, by End User USD Million (2013-2018)
  • Table 36. Asia Pacific Onychomycosis, by Country USD Million (2013-2018)
  • Table 37. Asia Pacific Onychomycosis, by Type USD Million (2013-2018)
  • Table 38. Asia Pacific Onychomycosis, by Application USD Million (2013-2018)
  • Table 39. Asia Pacific Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 40. Asia Pacific Onychomycosis, by End User USD Million (2013-2018)
  • Table 41. China Onychomycosis, by Type USD Million (2013-2018)
  • Table 42. China Onychomycosis, by Application USD Million (2013-2018)
  • Table 43. China Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 44. China Onychomycosis, by End User USD Million (2013-2018)
  • Table 45. Japan Onychomycosis, by Type USD Million (2013-2018)
  • Table 46. Japan Onychomycosis, by Application USD Million (2013-2018)
  • Table 47. Japan Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 48. Japan Onychomycosis, by End User USD Million (2013-2018)
  • Table 49. India Onychomycosis, by Type USD Million (2013-2018)
  • Table 50. India Onychomycosis, by Application USD Million (2013-2018)
  • Table 51. India Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 52. India Onychomycosis, by End User USD Million (2013-2018)
  • Table 53. South Korea Onychomycosis, by Type USD Million (2013-2018)
  • Table 54. South Korea Onychomycosis, by Application USD Million (2013-2018)
  • Table 55. South Korea Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 56. South Korea Onychomycosis, by End User USD Million (2013-2018)
  • Table 57. Taiwan Onychomycosis, by Type USD Million (2013-2018)
  • Table 58. Taiwan Onychomycosis, by Application USD Million (2013-2018)
  • Table 59. Taiwan Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 60. Taiwan Onychomycosis, by End User USD Million (2013-2018)
  • Table 61. Australia Onychomycosis, by Type USD Million (2013-2018)
  • Table 62. Australia Onychomycosis, by Application USD Million (2013-2018)
  • Table 63. Australia Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 64. Australia Onychomycosis, by End User USD Million (2013-2018)
  • Table 65. Rest of Asia-Pacific Onychomycosis, by Type USD Million (2013-2018)
  • Table 66. Rest of Asia-Pacific Onychomycosis, by Application USD Million (2013-2018)
  • Table 67. Rest of Asia-Pacific Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 68. Rest of Asia-Pacific Onychomycosis, by End User USD Million (2013-2018)
  • Table 69. Europe Onychomycosis, by Country USD Million (2013-2018)
  • Table 70. Europe Onychomycosis, by Type USD Million (2013-2018)
  • Table 71. Europe Onychomycosis, by Application USD Million (2013-2018)
  • Table 72. Europe Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 73. Europe Onychomycosis, by End User USD Million (2013-2018)
  • Table 74. Germany Onychomycosis, by Type USD Million (2013-2018)
  • Table 75. Germany Onychomycosis, by Application USD Million (2013-2018)
  • Table 76. Germany Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 77. Germany Onychomycosis, by End User USD Million (2013-2018)
  • Table 78. France Onychomycosis, by Type USD Million (2013-2018)
  • Table 79. France Onychomycosis, by Application USD Million (2013-2018)
  • Table 80. France Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 81. France Onychomycosis, by End User USD Million (2013-2018)
  • Table 82. Italy Onychomycosis, by Type USD Million (2013-2018)
  • Table 83. Italy Onychomycosis, by Application USD Million (2013-2018)
  • Table 84. Italy Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 85. Italy Onychomycosis, by End User USD Million (2013-2018)
  • Table 86. United Kingdom Onychomycosis, by Type USD Million (2013-2018)
  • Table 87. United Kingdom Onychomycosis, by Application USD Million (2013-2018)
  • Table 88. United Kingdom Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 89. United Kingdom Onychomycosis, by End User USD Million (2013-2018)
  • Table 90. Netherlands Onychomycosis, by Type USD Million (2013-2018)
  • Table 91. Netherlands Onychomycosis, by Application USD Million (2013-2018)
  • Table 92. Netherlands Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 93. Netherlands Onychomycosis, by End User USD Million (2013-2018)
  • Table 94. Rest of Europe Onychomycosis, by Type USD Million (2013-2018)
  • Table 95. Rest of Europe Onychomycosis, by Application USD Million (2013-2018)
  • Table 96. Rest of Europe Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 97. Rest of Europe Onychomycosis, by End User USD Million (2013-2018)
  • Table 98. MEA Onychomycosis, by Country USD Million (2013-2018)
  • Table 99. MEA Onychomycosis, by Type USD Million (2013-2018)
  • Table 100. MEA Onychomycosis, by Application USD Million (2013-2018)
  • Table 101. MEA Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 102. MEA Onychomycosis, by End User USD Million (2013-2018)
  • Table 103. Middle East Onychomycosis, by Type USD Million (2013-2018)
  • Table 104. Middle East Onychomycosis, by Application USD Million (2013-2018)
  • Table 105. Middle East Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 106. Middle East Onychomycosis, by End User USD Million (2013-2018)
  • Table 107. Africa Onychomycosis, by Type USD Million (2013-2018)
  • Table 108. Africa Onychomycosis, by Application USD Million (2013-2018)
  • Table 109. Africa Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 110. Africa Onychomycosis, by End User USD Million (2013-2018)
  • Table 111. North America Onychomycosis, by Country USD Million (2013-2018)
  • Table 112. North America Onychomycosis, by Type USD Million (2013-2018)
  • Table 113. North America Onychomycosis, by Application USD Million (2013-2018)
  • Table 114. North America Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 115. North America Onychomycosis, by End User USD Million (2013-2018)
  • Table 116. United States Onychomycosis, by Type USD Million (2013-2018)
  • Table 117. United States Onychomycosis, by Application USD Million (2013-2018)
  • Table 118. United States Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 119. United States Onychomycosis, by End User USD Million (2013-2018)
  • Table 120. Canada Onychomycosis, by Type USD Million (2013-2018)
  • Table 121. Canada Onychomycosis, by Application USD Million (2013-2018)
  • Table 122. Canada Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 123. Canada Onychomycosis, by End User USD Million (2013-2018)
  • Table 124. Mexico Onychomycosis, by Type USD Million (2013-2018)
  • Table 125. Mexico Onychomycosis, by Application USD Million (2013-2018)
  • Table 126. Mexico Onychomycosis, by Treatment USD Million (2013-2018)
  • Table 127. Mexico Onychomycosis, by End User USD Million (2013-2018)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Onychomycosis: by Type(USD Million)
  • Table 143. Onychomycosis Distal Subungual Onychomycosis , by Region USD Million (2019-2024)
  • Table 144. Onychomycosis White Superficial Onychomycosis , by Region USD Million (2019-2024)
  • Table 145. Onychomycosis Proximal Subungual Onychomycosis , by Region USD Million (2019-2024)
  • Table 146. Onychomycosis Candida Onychomycosis , by Region USD Million (2019-2024)
  • Table 147. Onychomycosis: by Application(USD Million)
  • Table 148. Onychomycosis Children , by Region USD Million (2019-2024)
  • Table 149. Onychomycosis Male Adults , by Region USD Million (2019-2024)
  • Table 150. Onychomycosis Female Adults , by Region USD Million (2019-2024)
  • Table 151. Onychomycosis Senior Citizens , by Region USD Million (2019-2024)
  • Table 152. Onychomycosis: by Treatment(USD Million)
  • Table 153. Onychomycosis Drug Treatment , by Region USD Million (2019-2024)
  • Table 154. Onychomycosis Tropical therapy , by Region USD Million (2019-2024)
  • Table 155. Onychomycosis Debridement , by Region USD Million (2019-2024)
  • Table 156. Onychomycosis: by End User(USD Million)
  • Table 157. Onychomycosis Hospital Pharmacies , by Region USD Million (2019-2024)
  • Table 158. Onychomycosis Private Pharmacies , by Region USD Million (2019-2024)
  • Table 159. Onychomycosis Others , by Region USD Million (2019-2024)
  • Table 160. South America Onychomycosis, by Country USD Million (2019-2024)
  • Table 161. South America Onychomycosis, by Type USD Million (2019-2024)
  • Table 162. South America Onychomycosis, by Application USD Million (2019-2024)
  • Table 163. South America Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 164. South America Onychomycosis, by End User USD Million (2019-2024)
  • Table 165. Brazil Onychomycosis, by Type USD Million (2019-2024)
  • Table 166. Brazil Onychomycosis, by Application USD Million (2019-2024)
  • Table 167. Brazil Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 168. Brazil Onychomycosis, by End User USD Million (2019-2024)
  • Table 169. Argentina Onychomycosis, by Type USD Million (2019-2024)
  • Table 170. Argentina Onychomycosis, by Application USD Million (2019-2024)
  • Table 171. Argentina Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 172. Argentina Onychomycosis, by End User USD Million (2019-2024)
  • Table 173. Rest of South America Onychomycosis, by Type USD Million (2019-2024)
  • Table 174. Rest of South America Onychomycosis, by Application USD Million (2019-2024)
  • Table 175. Rest of South America Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 176. Rest of South America Onychomycosis, by End User USD Million (2019-2024)
  • Table 177. Asia Pacific Onychomycosis, by Country USD Million (2019-2024)
  • Table 178. Asia Pacific Onychomycosis, by Type USD Million (2019-2024)
  • Table 179. Asia Pacific Onychomycosis, by Application USD Million (2019-2024)
  • Table 180. Asia Pacific Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 181. Asia Pacific Onychomycosis, by End User USD Million (2019-2024)
  • Table 182. China Onychomycosis, by Type USD Million (2019-2024)
  • Table 183. China Onychomycosis, by Application USD Million (2019-2024)
  • Table 184. China Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 185. China Onychomycosis, by End User USD Million (2019-2024)
  • Table 186. Japan Onychomycosis, by Type USD Million (2019-2024)
  • Table 187. Japan Onychomycosis, by Application USD Million (2019-2024)
  • Table 188. Japan Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 189. Japan Onychomycosis, by End User USD Million (2019-2024)
  • Table 190. India Onychomycosis, by Type USD Million (2019-2024)
  • Table 191. India Onychomycosis, by Application USD Million (2019-2024)
  • Table 192. India Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 193. India Onychomycosis, by End User USD Million (2019-2024)
  • Table 194. South Korea Onychomycosis, by Type USD Million (2019-2024)
  • Table 195. South Korea Onychomycosis, by Application USD Million (2019-2024)
  • Table 196. South Korea Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 197. South Korea Onychomycosis, by End User USD Million (2019-2024)
  • Table 198. Taiwan Onychomycosis, by Type USD Million (2019-2024)
  • Table 199. Taiwan Onychomycosis, by Application USD Million (2019-2024)
  • Table 200. Taiwan Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 201. Taiwan Onychomycosis, by End User USD Million (2019-2024)
  • Table 202. Australia Onychomycosis, by Type USD Million (2019-2024)
  • Table 203. Australia Onychomycosis, by Application USD Million (2019-2024)
  • Table 204. Australia Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 205. Australia Onychomycosis, by End User USD Million (2019-2024)
  • Table 206. Rest of Asia-Pacific Onychomycosis, by Type USD Million (2019-2024)
  • Table 207. Rest of Asia-Pacific Onychomycosis, by Application USD Million (2019-2024)
  • Table 208. Rest of Asia-Pacific Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 209. Rest of Asia-Pacific Onychomycosis, by End User USD Million (2019-2024)
  • Table 210. Europe Onychomycosis, by Country USD Million (2019-2024)
  • Table 211. Europe Onychomycosis, by Type USD Million (2019-2024)
  • Table 212. Europe Onychomycosis, by Application USD Million (2019-2024)
  • Table 213. Europe Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 214. Europe Onychomycosis, by End User USD Million (2019-2024)
  • Table 215. Germany Onychomycosis, by Type USD Million (2019-2024)
  • Table 216. Germany Onychomycosis, by Application USD Million (2019-2024)
  • Table 217. Germany Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 218. Germany Onychomycosis, by End User USD Million (2019-2024)
  • Table 219. France Onychomycosis, by Type USD Million (2019-2024)
  • Table 220. France Onychomycosis, by Application USD Million (2019-2024)
  • Table 221. France Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 222. France Onychomycosis, by End User USD Million (2019-2024)
  • Table 223. Italy Onychomycosis, by Type USD Million (2019-2024)
  • Table 224. Italy Onychomycosis, by Application USD Million (2019-2024)
  • Table 225. Italy Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 226. Italy Onychomycosis, by End User USD Million (2019-2024)
  • Table 227. United Kingdom Onychomycosis, by Type USD Million (2019-2024)
  • Table 228. United Kingdom Onychomycosis, by Application USD Million (2019-2024)
  • Table 229. United Kingdom Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 230. United Kingdom Onychomycosis, by End User USD Million (2019-2024)
  • Table 231. Netherlands Onychomycosis, by Type USD Million (2019-2024)
  • Table 232. Netherlands Onychomycosis, by Application USD Million (2019-2024)
  • Table 233. Netherlands Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 234. Netherlands Onychomycosis, by End User USD Million (2019-2024)
  • Table 235. Rest of Europe Onychomycosis, by Type USD Million (2019-2024)
  • Table 236. Rest of Europe Onychomycosis, by Application USD Million (2019-2024)
  • Table 237. Rest of Europe Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 238. Rest of Europe Onychomycosis, by End User USD Million (2019-2024)
  • Table 239. MEA Onychomycosis, by Country USD Million (2019-2024)
  • Table 240. MEA Onychomycosis, by Type USD Million (2019-2024)
  • Table 241. MEA Onychomycosis, by Application USD Million (2019-2024)
  • Table 242. MEA Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 243. MEA Onychomycosis, by End User USD Million (2019-2024)
  • Table 244. Middle East Onychomycosis, by Type USD Million (2019-2024)
  • Table 245. Middle East Onychomycosis, by Application USD Million (2019-2024)
  • Table 246. Middle East Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 247. Middle East Onychomycosis, by End User USD Million (2019-2024)
  • Table 248. Africa Onychomycosis, by Type USD Million (2019-2024)
  • Table 249. Africa Onychomycosis, by Application USD Million (2019-2024)
  • Table 250. Africa Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 251. Africa Onychomycosis, by End User USD Million (2019-2024)
  • Table 252. North America Onychomycosis, by Country USD Million (2019-2024)
  • Table 253. North America Onychomycosis, by Type USD Million (2019-2024)
  • Table 254. North America Onychomycosis, by Application USD Million (2019-2024)
  • Table 255. North America Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 256. North America Onychomycosis, by End User USD Million (2019-2024)
  • Table 257. United States Onychomycosis, by Type USD Million (2019-2024)
  • Table 258. United States Onychomycosis, by Application USD Million (2019-2024)
  • Table 259. United States Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 260. United States Onychomycosis, by End User USD Million (2019-2024)
  • Table 261. Canada Onychomycosis, by Type USD Million (2019-2024)
  • Table 262. Canada Onychomycosis, by Application USD Million (2019-2024)
  • Table 263. Canada Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 264. Canada Onychomycosis, by End User USD Million (2019-2024)
  • Table 265. Mexico Onychomycosis, by Type USD Million (2019-2024)
  • Table 266. Mexico Onychomycosis, by Application USD Million (2019-2024)
  • Table 267. Mexico Onychomycosis, by Treatment USD Million (2019-2024)
  • Table 268. Mexico Onychomycosis, by End User USD Million (2019-2024)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Onychomycosis: by Type USD Million (2013-2018)
  • Figure 5. Global Onychomycosis: by Application USD Million (2013-2018)
  • Figure 6. Global Onychomycosis: by Treatment USD Million (2013-2018)
  • Figure 7. Global Onychomycosis: by End User USD Million (2013-2018)
  • Figure 8. South America Onychomycosis Share (%), by Country
  • Figure 9. Asia Pacific Onychomycosis Share (%), by Country
  • Figure 10. Europe Onychomycosis Share (%), by Country
  • Figure 11. MEA Onychomycosis Share (%), by Country
  • Figure 12. North America Onychomycosis Share (%), by Country
  • Figure 13. Global Onychomycosis share by Players 2018 (%)
  • Figure 14. Global Onychomycosis share by Players (Top 3) 2018(%)
  • Figure 15. Global Onychomycosis share by Players (Top 5) 2018(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories Ltd. (United States) Revenue: by Geography 2018
  • Figure 19. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2018
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2018
  • Figure 23. Valeant Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 24. Valeant Pharmaceuticals (Canada) Revenue: by Geography 2018
  • Figure 25. Galderma (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Galderma (Switzerland) Revenue: by Geography 2018
  • Figure 27. Janssen Biotech (United States) Revenue, Net Income and Gross profit
  • Figure 28. Janssen Biotech (United States) Revenue: by Geography 2018
  • Figure 29. Sciton Inc (United States) Revenue, Net Income and Gross profit
  • Figure 30. Sciton Inc (United States) Revenue: by Geography 2018
  • Figure 31. Bristol Meyer Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 32. Bristol Meyer Squibb Company (United States) Revenue: by Geography 2018
  • Figure 33. Cutera Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Cutera Inc. (United States) Revenue: by Geography 2018
  • Figure 35. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 36. Novartis AG (Switzerland) Revenue: by Geography 2018
  • Figure 37. Sanofi Ltd. (France) Revenue, Net Income and Gross profit
  • Figure 38. Sanofi Ltd. (France) Revenue: by Geography 2018
  • Figure 39. Topica Pharmaceuticals Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Topica Pharmaceuticals Inc. (United States) Revenue: by Geography 2018
  • Figure 41. Taro Pharmaceutical Industries Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Taro Pharmaceutical Industries Ltd. (United States) Revenue: by Geography 2018
  • Figure 43. Seren Pharmaceuticals Pvt. Ltd (China) Revenue, Net Income and Gross profit
  • Figure 44. Seren Pharmaceuticals Pvt. Ltd (China) Revenue: by Geography 2018
  • Figure 45. Global Onychomycosis: by Type USD Million (2019-2024)
  • Figure 46. Global Onychomycosis: by Application USD Million (2019-2024)
  • Figure 47. Global Onychomycosis: by Treatment USD Million (2019-2024)
  • Figure 48. Global Onychomycosis: by End User USD Million (2019-2024)
  • Figure 49. South America Onychomycosis Share (%), by Country
  • Figure 50. Asia Pacific Onychomycosis Share (%), by Country
  • Figure 51. Europe Onychomycosis Share (%), by Country
  • Figure 52. MEA Onychomycosis Share (%), by Country
  • Figure 53. North America Onychomycosis Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Abbott Laboratories Ltd. (United States)
  • GlaxoSmithKline Plc. (United Kingdom)
  • Pfizer Inc. (United States)
  • Valeant Pharmaceuticals (Canada)
  • Galderma (Switzerland)
  • Janssen Biotech (United States)
  • Sciton Inc (United States)
  • Bristol Meyer Squibb Company (United States)
  • Cutera Inc. (United States)
  • Novartis AG (Switzerland)
  • Sanofi Ltd. (France)
  • Topica Pharmaceuticals Inc. (United States)
  • Taro Pharmaceutical Industries Ltd. (United States)
  • Seren Pharmaceuticals Pvt. Ltd (China)
Additional players considered in the study are as follows:
Nuvo Research Inc. (Canada) , Merz Pharma gmbh & co. kgaa (Germany) , NanoBio Corporation (United States) , NovaBiotics Ltd (UKUnited Kingdom) , Viamet Pharmaceuticals Inc. (United States) , Polichem SA (Switzerland)
Select User Access Type

Key Highlights of Report


Jul 2019 235 Pages 76 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Onychomycosis Quantitative research analysis
Global Onychomycosis Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Onychomycosis Report?

Have a Query? Click Here

Other Related Reports

Sports Medicine Products Comprehensive Study by Type (Body reconstruction products, Body support & recovery products, Medical accessories), Application (Shoulder injuries, Foot and ankle injuries, El...
$ 3750
Tuberculin Comprehensive Study by Type (PPD-S, PPD RT23, Others), Application (Human Use, Animal Use), Therapy (First-Line Therapy, Second-Line Therapy) Players and Region - Global Market Outlook to ...
$ 3500
Homeopathy Comprehensive Study by Type (Tincture, Dilutions, Biochemics, Ointments, Tablets), Application (Respiratory, Neurology, Immunology, Gastroenterology, Dermatology, Others), Treatment (Auto-...
$ 3650
Medical Lab Software Comprehensive Study by Application (PC Terminal, Mobile Terminal), End users (Health Care, Medical Lab, Others), Services (MEDICAL LABORATORY MANAGEMENT, REPORTS, BILLING, TEST R...
$ 3450
Professional Dental Care Comprehensive Study by Type (Toothpastes, Toothbrushes, Mouthwashes/Rinses, Dental Accessories/Ancillaries, Denture Products), Application (Hospital, Clinic, Other) Players a...
$ 3500
Veterinary Pain Management Comprehensive Study by Type (Drugs {NSAIDs, Opiods}, Devices {Laser, Electromagnetic}), Application (Joint Pain {Osteoarthritis, Musculoskeletal Disorders}, Postoperative P...
$ 3650